Vaccines included in the GSK Vaccines Access Program include CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant], TWINRIX [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine], HAVRIX [Hepatitis A Inactivated], ENGERIX-B [Hepatitis B Vaccine (Recombinant)], BOOSTRIX
[Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed].
Asi Ticari Adi Koruyucu Bakteri asilari DTaP Infanrix[R] 2-Fenoksietanol DAPTACEL[TM] -- Tripedia[R] -- Tdap ADACEL[TM] -- BOOSTRIX
-- Td (eriskin) DECAVAC[R] -- Virus Asilari Hepatit A Havrix[R] 2-Fenoksietanol VAOTA[R] -- Influenza Fluarix[TM] Timerosal Fluvirin[R] -- (fek doz) Fluvirin[R] Timerosal (Multi doz) Japon JE-VAX[R] Timerosal ensefalit virusu Polio IPOL[R] 2-Fenoksietanol ve formaldehid Kuduz Imovax[R] -- RabAvert[R] -- Asi Ticari Adi Adjuvan Bakteri asilari DTaP Infanrix[R] Al[(OH).
BOOSTRIX may not protect 100% of individuals receiving the vaccine
Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication
Food and Drug Administration (FDA) has approved BOOSTRIX [Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine, Adsorbed (Tdap)] for use in adults 65 years of age and older for active booster immunization against tetanus, diphtheria and pertussis (whooping cough).
In the news release, Video from GlaxoSmithKline and Synaptic Digital: GlaxoSmithKline Receives FDA Approval for BOOSTRIX to Help Prevent Whooping Cough in Adults 65 Years and Older, issued 08-Jul-2011 by Synaptic Digital over PR Newswire, we are advised by the company that the headline should now read, "GlaxoSmithKline Receives FDA approval for BOOSTRIX to Help Prevent Whooping Cough in Adults 65 Years and Older.
BOOSTRIX is available in vials and 2 types of prefilled syringes.
The decision to give BOOSTRIX should be based on benefits and risks if Guillain-Barre syndrome occurred within 6 weeks of receipt of a prior tetanus toxoid-containing vaccine
Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus toxoid-containing vaccine should not receive BOOSTRIX unless 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine
BOOSTRIX was first approved for individuals aged 10-18 in May 2005.